美股异动 | 诺和诺德(NVO.US)涨近3% Wegovy在美获批用于治疗脂肪肝

Core Viewpoint - Novo Nordisk's Wegovy has received FDA approval for a new indication to treat metabolic associated fatty liver disease (MASH) with moderate to severe liver fibrosis in non-cirrhotic adult patients, marking it as the first GLP-1 drug approved for this condition [1] Group 1 - Novo Nordisk's stock rose nearly 3% to $55.33 following the FDA approval announcement [1] - The approval is based on a supplemental new drug application (sNDA) [1] - Wegovy is now positioned uniquely as the first and only GLP-1 drug approved for treating MASH [1]